EP1937851A4 - METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE - Google Patents

METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE

Info

Publication number
EP1937851A4
EP1937851A4 EP06785922A EP06785922A EP1937851A4 EP 1937851 A4 EP1937851 A4 EP 1937851A4 EP 06785922 A EP06785922 A EP 06785922A EP 06785922 A EP06785922 A EP 06785922A EP 1937851 A4 EP1937851 A4 EP 1937851A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
increased complexity
bioactive assemblies
generating bioactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06785922A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1937851A2 (en
Inventor
Chien-Hsing Chang
David M Goldenberg
William J Mcbride
Edmund A Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IBC Pharmaceuticals Inc
Original Assignee
IBC Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/010762 external-priority patent/WO2006107617A2/en
Priority claimed from US11/389,358 external-priority patent/US7550143B2/en
Priority claimed from PCT/US2006/012084 external-priority patent/WO2006107786A2/en
Application filed by IBC Pharmaceuticals Inc filed Critical IBC Pharmaceuticals Inc
Publication of EP1937851A2 publication Critical patent/EP1937851A2/en
Publication of EP1937851A4 publication Critical patent/EP1937851A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
EP06785922A 2005-10-19 2006-06-29 METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE Withdrawn EP1937851A4 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US72829205P 2005-10-19 2005-10-19
US75119605P 2005-12-16 2005-12-16
US78233206P 2006-03-14 2006-03-14
PCT/US2006/010762 WO2006107617A2 (en) 2005-04-06 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US11/389,358 US7550143B2 (en) 2005-04-06 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US11/391,584 US7521056B2 (en) 2005-04-06 2006-03-28 Stably tethered structures of defined compositions with multiple functions or binding specificities
PCT/US2006/012084 WO2006107786A2 (en) 2005-04-06 2006-03-29 Improved stably tethered structures of defined compositions with multiple functions or binding specificities
PCT/US2006/025499 WO2007046893A2 (en) 2005-10-19 2006-06-29 Methods for generating bioactive assemblies and uses thereof

Publications (2)

Publication Number Publication Date
EP1937851A2 EP1937851A2 (en) 2008-07-02
EP1937851A4 true EP1937851A4 (en) 2010-08-25

Family

ID=40666724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06785922A Withdrawn EP1937851A4 (en) 2005-10-19 2006-06-29 METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE

Country Status (5)

Country Link
EP (1) EP1937851A4 (cg-RX-API-DMAC7.html)
JP (1) JP5231231B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006302848C1 (cg-RX-API-DMAC7.html)
CA (1) CA2607056C (cg-RX-API-DMAC7.html)
WO (1) WO2007046893A2 (cg-RX-API-DMAC7.html)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US8491914B2 (en) 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US8883162B2 (en) 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20100226884A1 (en) 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
WO2012024223A2 (en) * 2010-08-17 2012-02-23 Immunomedics, Inc. Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
BRPI0911427A2 (pt) * 2008-04-10 2015-11-17 Ibc Pharmaceuticals complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica.
AU2009256547B2 (en) 2008-06-13 2014-07-10 Proyecto De Biomedicina Cima, S.L. Apo-A conjugates for the administration of biologically active compounds
CA2734265C (en) * 2008-08-20 2017-12-19 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
WO2010033249A2 (en) 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
US20100278829A1 (en) * 2009-02-06 2010-11-04 Edwards Iii Carl Keith Dual inhibition of immunophilin/cyclophilin family members and emmprin immunoglobulin receptor superfamily members
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
EP2473186A4 (en) * 2009-08-31 2013-07-10 Ibc Pharmaceuticals Inc BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF
EP2473187A4 (en) * 2009-08-31 2015-09-16 Immunomedics Inc COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
WO2011029980A1 (es) 2009-09-11 2011-03-17 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por hpv
CA2776563A1 (en) * 2009-11-05 2011-05-12 Center For Molecular Medicine And Immunology Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
CN102665758A (zh) 2009-12-09 2012-09-12 Ibc药品公司 用于递送干扰rna的对接锁定(dnl)复合物
EP2509630A4 (en) * 2009-12-09 2013-07-17 Immunomedics Inc SYSTEM FOR PROCESSING CYTOTOXIC REMEDIES THROUGH BISPECIFIC ANTIBODY TARGET
US10822396B2 (en) 2009-12-15 2020-11-03 MuHyeon CHOE Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
AU2009356549B2 (en) * 2009-12-15 2012-12-06 Muhyeon Choe Method for manufacturing dimers and multimers in complexes of multiple monomers and repeat chains of affinity domains binding specifically to monomers with increasing the formation of inter-monomeric bond bridges among monomers
WO2011090492A1 (en) * 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
EP2555788B1 (en) 2010-03-24 2017-10-11 Massachusetts Institute of Technology NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY.
EP2588525A4 (en) 2010-06-29 2015-06-10 Covidien Lp MICROWAVE POWERED REACTOR AND IN SITU IMPLANT TRAINING METHOD
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
AU2011323354B2 (en) * 2010-11-03 2014-07-31 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CN103160513B (zh) * 2011-12-16 2015-07-01 中国医学科学院基础医学研究所 Muc1蛋白核酸适配子、复合体、组合物及其用途
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
CN104363919A (zh) 2012-06-01 2015-02-18 Ibc药品公司 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
CN102703453B (zh) * 2012-06-13 2013-10-30 江南大学 特异性识别链霉素的dna适配体及其应用
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
ITRM20130138A1 (it) 2013-03-07 2014-09-08 Consiglio Nazionale Ricerche Assemblato comprendente un assorbitore della luce nel vicino infrarosso legato covalentemente ad un inibitore dell'anidrasi carbonica
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
US9416197B2 (en) 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
FR3017714A1 (fr) * 2014-02-18 2015-08-21 Biomerieux Sa Procede et kit pour determiner la probabilite pour un patient d'evoluer vers une dengue severe
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
CN113549153A (zh) 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
RU2017129236A (ru) 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
CN104558174A (zh) * 2015-01-29 2015-04-29 东南大学 一种针对睾酮的特异性纳米抗体及其应用
IL297418B2 (en) 2015-02-18 2023-11-01 Enlivex Therapeutics Rdo Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016250570B2 (en) 2015-04-21 2021-07-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2016191481A1 (en) 2015-05-28 2016-12-01 Immunomedics, Inc. T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
SMT202100527T1 (it) 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
BR112018006817A2 (pt) 2015-10-08 2018-10-23 Macrogenics Inc método de tratamento do câncer
KR102106619B1 (ko) * 2015-10-12 2020-05-06 진메디신 주식회사 유전자 전달 및 유전자 치료를 위한 아데노바이러스 복합체
EP3385383B1 (en) * 2015-12-04 2021-04-07 Zenyaku Kogyo Co., Ltd. Anti-il-17 aptamer having improved retention in blood
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
ES3013312T3 (en) 2015-12-17 2025-04-11 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
US20170233472A1 (en) 2016-02-17 2017-08-17 Macrogenics, Inc. ROR1-Binding Molecules, and Methods of Use Thereof
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
KR102630036B1 (ko) 2016-12-23 2024-01-29 마크로제닉스, 인크. Adam9-결합 분자, 및 이것의 사용 방법
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CN109771658B (zh) * 2017-11-14 2021-12-10 博瑞生物医药（苏州）股份有限公司 靶向多臂偶联物
KR20200098590A (ko) 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
EP4021909A4 (en) 2019-08-29 2023-08-30 David C. Martin Biofunctional thiophene monomers
US12435155B2 (en) 2020-02-21 2025-10-07 Macrogenics, Inc. CD137 binding molecules and uses thereof
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
EP4175650A1 (en) 2020-07-06 2023-05-10 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
CN112156194B (zh) * 2020-09-29 2023-01-24 中国工程物理研究院核物理与化学研究所 一种去除177Lu溶液中内毒素的方法
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
CN115976196B (zh) * 2022-12-16 2024-12-06 深圳市人民医院 ErbB3作为肺动脉高压生物标志物和治疗靶点的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198956A1 (en) * 2002-02-21 2003-10-23 Lee Makowski Staged assembly of nanostructures
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2006107617A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
DE69942148D1 (de) * 1998-06-22 2010-04-29 Immunomedics Inc Gebrauch von bispezifischen antikörpern in diagnose und therapie
US7060506B2 (en) * 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
CA2503787A1 (en) * 2002-11-05 2004-05-27 Regeneron Pharmaceuticals, Inc. Methods of isolation of active compounds and activated targets
DE602004001395T2 (de) * 2003-02-13 2007-08-09 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198956A1 (en) * 2002-02-21 2003-10-23 Lee Makowski Staged assembly of nanostructures
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2006107617A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BANKY P ET AL: "Dimerization/docking domain of the type Ialpha regulatory subunit of cAMP-dependent protein kinase. Requirements for dimerization and docking are distinct but overlapping.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 DEC 1998, vol. 273, no. 52, 25 December 1998 (1998-12-25), pages 35048 - 35055, XP002555878, ISSN: 0021-9258 *
CHANG CHIEN-HSING ET AL: "The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 SEP 2007 LNKD- PUBMED:17875793, vol. 13, no. 18 Pt 2, 15 September 2007 (2007-09-15), pages 5586s - 5591s, XP009112546, ISSN: 1078-0432, DOI: 10.1158/1078-0432 *
CHIEN-HSING CHANG ET AL: "A New Method to Produce MonoPEGylated Dimeric Cytokines Shown with Human Interferon-[alpha]2b", BIOCONJUGATE CHEMISTRY, vol. 20, no. 10, 21 October 2009 (2009-10-21), pages 1899 - 1907, XP055022032, ISSN: 1043-1802, DOI: 10.1021/bc9001773 *
DEYEV S M ET AL: "Design of multivalent complexes using the barnase-barstar module", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 21, no. 12, 1 December 2003 (2003-12-01), pages 1486 - 1492, XP002372739, ISSN: 1087-0156 *
EDMUND A ROSSI ET AL: "Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics", vol. 68, no. 20, 15 October 2008 (2008-10-15), pages 8384 - 8392, XP002698652, ISSN: 0008-5472, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/68/20/8384> DOI: 10.1158/0008-5472.CAN-08-2033 *
GOLDENBERG DAVID M ET AL: "Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting.", JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE JAN 2008 LNKD- PUBMED:18077530, vol. 49, no. 1, January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 *
NEWLON M G ET AL: "The molecular basis for protein kinase A anchoring revealed by solution NMR.", NATURE STRUCTURAL BIOLOGY MAR 1999, vol. 6, no. 3, March 1999 (1999-03-01), pages 222 - 227, XP002555877, ISSN: 1072-8368 *
OYEN O ET AL: "Human testis cDNA for the regulatory subunit RIIalpha of CAMP-dependent protein kinase encodes an alternate amino-terminal region", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 246, no. 1-2, 27 March 1989 (1989-03-27), pages 57 - 64, XP025652754, ISSN: 0014-5793, [retrieved on 19890327] *
PLUCKTHUN A ET AL: "New protein engineering approaches to multivalent and bispecific antibody fragments", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 2, 1 June 1997 (1997-06-01), pages 83 - 105, XP004126672, ISSN: 1380-2933 *
ROSSI E A ET AL: "Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 10, PART 2, 1 September 2003 (2003-09-01), pages 3886S - 3896S, XP002259779, ISSN: 1078-0432 *
ROSSI EDMUND A ET AL: "A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.", CANCER RESEARCH 1 OCT 2010 LNKD- PUBMED:20876805, vol. 70, no. 19, 1 October 2010 (2010-10-01), pages 7600 - 7609, ISSN: 1538-7445 *
ROSSI EDMUND A ET AL: "CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.", BLOOD 29 OCT 2009 LNKD- PUBMED:19710501, vol. 114, no. 18, 29 October 2009 (2009-10-29), pages 3864 - 3871, XP055215756, ISSN: 1528-0020, DOI: 10.1182/blood-2009-06-228890 *
SHARKEY ROBERT M ET AL: "Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS FEB 2010 LNKD- PUBMED:20187791, vol. 25, no. 1, February 2010 (2010-02-01), pages 1 - 12, ISSN: 1557-8852 *
SHARKEY ROBERT M ET AL: "Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.", CANCER RESEARCH 1 JUL 2008 LNKD- PUBMED:18593929, vol. 68, no. 13, 1 July 2008 (2008-07-01), pages 5282 - 5290, XP055273512, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-08-0037 *
SHARKEY ROBERT M ET AL: "Optimizing bispecific antibody pretargeting for use in radioimmunotherapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 10, 1 September 2003 (2003-09-01), pages 3897S - 3913S, XP009099022, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
CA2607056C (en) 2015-11-24
EP1937851A2 (en) 2008-07-02
WO2007046893A3 (en) 2009-04-23
WO2007046893A2 (en) 2007-04-26
AU2006302848C1 (en) 2012-08-02
JP2009517337A (ja) 2009-04-30
AU2006302848B2 (en) 2012-02-23
JP5231231B2 (ja) 2013-07-10
AU2006302848A1 (en) 2007-04-26
CA2607056A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
EP1937851A4 (en) METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE
PL1845803T3 (pl) Sposób wytwarzania kompozycji suszonych rozpryskowo oraz ich zastosowania
IL192098A (en) Preparations and Methods for Manufacturing Preparations
PL3398606T3 (pl) Kompozycje otrzymane z mikroalg poprawiające zdrowie i wygląd skóry
IL186973A0 (en) Compositions and methods for treatment for neoplasms
PL1899364T3 (pl) Kompozycje i sposoby immunomodulacji w organizmie
ZA200805640B (en) Terpene-containing compositions and methods of making and using them
IL191072A0 (en) Therapeutic compositions and methods
IL185540A0 (en) Compositions and methods for treating acne
IL196465A0 (en) Compositions and methods for the treatment of mucositis
IL190885A0 (en) Immunogenic compositions and methods of use
ZA200710983B (en) Bacterial cellulose-containing formulations and method of producing effective bacterial cellulose-containing formulations
GB0522287D0 (en) Method and compositions
IL190520A0 (en) Compositions and methods for treatment of autoimmune
EP1968526A4 (en) FOAMING DENTAL COMPOSITIONS AND METHODS
IL190583A0 (en) Pth formulations and methods of use
EP1937075A4 (en) SYNERGIC COMPOSITION AND METHOD OF USE
IL186606A0 (en) Compositions and uses of amooranin compounds
GB0524927D0 (en) Compositions and method
ZA200707529B (en) Pro-fragrance and pro-flavorant compositions
GB0520930D0 (en) Composition and method of use
EP2046109A4 (en) PHOTOSYNTHETIC ORGANISMS, COMPOSITIONS AND METHODS FOR GENERATING THESE ORGANISMS
GB2423081B (en) Pro-fragrance and pro-flavorant compositions
GB0511235D0 (en) Compositions and method
GB0504657D0 (en) Compositions and methods of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071018

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20090423

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20090623BHEP

Ipc: C07K 16/46 20060101ALI20090623BHEP

Ipc: A61K 39/395 20060101ALI20090623BHEP

Ipc: A61K 38/16 20060101ALI20090623BHEP

Ipc: A61K 31/00 20060101ALI20090623BHEP

Ipc: C07K 19/00 20060101ALI20090623BHEP

Ipc: C07K 17/00 20060101ALI20090623BHEP

Ipc: A61K 103/00 20060101ALI20090623BHEP

Ipc: A61K 51/00 20060101AFI20090623BHEP

Ipc: C07K 14/00 20060101ALI20090623BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100722

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20100716BHEP

Ipc: C07K 16/28 20060101AFI20100716BHEP

17Q First examination report despatched

Effective date: 20110727

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180412